Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Frank Misselwitz, Eva Muehlhofer, Peter KäleboVolume:
120
Year:
2007
Language:
english
DOI:
10.1016/j.thromres.2006.12.025
File:
PDF, 302 KB
english, 2007